Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents

Neuropsychopharmacology

Volumn 28, Issue 1, 2003, Pages 1-13

  Marx, Christine E ^a   Van Doren, Margaret J ^c   Duncan, Gary E ^b   Lieberman, Jeffrey A ^b   Morrow, A Leslie ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Allopregnanolone; Clozapine; GABA; Neuroactive steroid; Olanzapine; Progesterone

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; CORTICOSTERONE; DRUG DERIVATIVE; ELTANOLONE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE; PROGESTERONE; RISPERIDONE; SEX HORMONE;

ADRENALECTOMY; ANIMAL; ARTICLE; BLOOD; BRAIN CORTEX; DOSE RESPONSE; DRUG EFFECT; MALE; METABOLISM; PHYSIOLOGY; RADIOIMMUNOASSAY; RAT; SPRAGUE DAWLEY RAT;

ADRENALECTOMY; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CLOZAPINE; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; GONADAL STEROID HORMONES; HALOPERIDOL; MALE; PIRENZEPINE; PREGNANOLONE; PROGESTERONE; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE;

EID: 0037208990     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300015     Document Type: Article

References (107)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers Met al(1998). Increased striatal dopamine transmission inschizophrenia: confirmation in a second cohort.Am J Psychiatry155: 761-767.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS etal(2000). Increased baseline occupancy ofD2receptors by dopamine in schizophrenia.ProcNatlAcadSciUSA97: 8104-8109.
3. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WEet al(1995). Gene expression for glutamic acid decarbox-ylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.Arch Gen Psychiatry52: 258-266.
4. Angermeyer MC, Kuhn L, Goldstein JM (1990). Gender and the course of schizophrenia: differences in treated outcomes.Schizophrenia Bull16: 293-307.
5. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levelsof D-amphetamine.Eur J Pharmacol283: 55-62.
6. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology18: 63-101.
7. Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA, Nestler EJ (1999). Region-specific induction of DfosB byrepeated administration of typical versus atypical antipsychoticdrugs.Synapse33: 118-128.
8. Barbaccia ML, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G (2001). Clozapine, but not haloperidol, increases brainconcentrations of neuroactive steroids in the rat.Neuropsycho-pharmacology25: 489-497.
9. Baulieu E-E, Schumacher M (2000). Progesterone as a neuroactiveneurosteroid, with special reference to the effect of progesteroneon myelination.Steroids65: 605-612.
10. Benes FM, Berretta S (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.Neuropsychopharmacology25: 1-27.
11. Belelli D, Bolger MB, Kelvin GW (1989). Anticonvulsant profile of the progesterone metabolite 5a-pregnan-3a-ol-20-one.Eur JPharmacol166: 325-329.
12. Breier A, Buchanan RW (1992). The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenicpatients.Life Sci51: 1527-1534.
13. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis Aet al(1997). Schizophrenia is associated withelevated amphetamine-induced synaptic dopamine concentra-tions.ProcNatlAcadSciUSA 94: 2569-2574.
14. Breier AF, Malhotra AK, Tung-Ping S, Pinals DA, Elman I, Adler CM etal(1999). Clozapine and risperidone inchronic schizophrenia: effects on symptoms, Parkinsonian sideeffects and neuroendocrine response.Am Jpsychiatry156:294-298.
15. Carpenter WT, Buchanan RW, Kirkpatrick B, Breier AF (1999). Diazepam treatment of early signs of exacerbation in schizo-phrenia.Am J Psychiatry156: 299-303.
16. Chan JR, Phillips LJ, Glaser M (1998). Glucocorticoids and progestins signal the initiation and enhance the rate of myelinformation.ProcNatlAcadSci USA95: 10459-10464.
17. Crawley JN, Glowa JR, Majewska MD, Paul SM (1986).Anxiolytic activity of an endogenous adrenal steroid.Brain Res398:382-385.
18. Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization.Am J Psychia-try148: 1474-1486.
19. Devaud LL, Purdy RH, Morrow AL (1995). The neurosteroid 3a-hydroxy-5a-pregnan-20-one, protects against bicuculline-in-duced seizures during ethanol withdrawal in rats.Alcoholism ClinExp Res19: 350-355.
20. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (2000).Comparison of the effects of clozapine, risperidone, andolanzapine on ketamine-induced alterations in regional brainmetabolism.J PharmacolExpTher29: 8-14.
21. Elman I, Breier A (1997). Effects of acute metabolic stress on plasma progesterone and testosterone in male subjects: relationship to pituitary-adrenocortical axis activation.Life Sci61:1705-1712.
22. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1and D2 dopamine receptor occupancy in patients treated withclassical neuroleptics and clozapine: relation to extrapyramidalside effects.Arch Gen Psychiatry49: 538-544.
23. Feder HH, Ruf KB (1969).Stimulation of progesterone release and estrous behavior by ACTH in ovariectomized rodents.Endocri-nology84: 171-174.
24. Finn DA, Gee KW (1994). The estrus cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactivesteroid.J PharmacolExpTher271: 164-170.
25. Gasior M, Carter RB, Goldberg SR, Witkin JM (1997). Antic-onvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam.J PharmacolExpTher282:543-553.
26. Genazzani AR, Petragilia F, Bernardi F, Casarosa E, Salvestrone C, Tonetti Aet al(1998). Circulating levels of allopregnanolone inhumans: gender, age, and endocrine influences.J ClinEndocri-nolMetab83: 2099-2103.
27. George DT, Lindquist T, Alim T, Flood M, Eckardt MJ, Linnoila M (1994). Abstinent alcoholics exhibit an exaggerated stressresponse to 2-deoxy-D-glucose challenge.Alcoholism ClinExpRes18: 685-691.
28. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL (2001). Allopregnanolone levels and reactivity to mental stress inpremenstrual dysphoric disorder.Biol Psychiatry49: 788-797.
29. Goldstein M, Deutch AY (1992). Dopaminergic mechanisms in the pathogenesis of schizophrenia.FASEB J6: 2413-2421.
30. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman Iet al (2000).Clozapine in the treatment of refractory psychotic mania.Am J Psychiatry157: 982-986.
31. Griffin LD, Mellon SH (1999). Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.ProcNatlAcadSci USA96: 13512-13517.
32. Grobin AC, Roth RH, Deutch AY (1992). Regulation of the prefrontal cortical dopamine system by the neuroactive steroid3a,21-dihydroxy-5a-pregnane-20-one.Brain Res578: 351-356.
33. Guo AL, Petraglia F, Criscuolo M, Ficarra G, Nappi RE, Palumbo MA (1995). Evidence for a role of neurosteroids in modulation ofdiurnal changes and acute stress-induced corticosteronesecre-tion in rats.GynecolEndocrinol9: 1-7.
34. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JDet al (2001). Genome-wide expression analysis reveals dysregulationof myelination-related genes in chronic schizophrenia.ProcNatlAcadSci USA98: 4746-4751.
35. Inoue T, Tsuchiya K, Koyama T (1996). Effects of typical and atypical antipsychotic drugs on freezing behavior induced byconditioned fear.PharmacolBiochem Behavior55: 195-201.
36. Janis GC, Devaud LL, Mitsuyama H, Morrow AL (1998). Effects of chronic ethanol consumption and withdrawal on the neuroactivesteroid 3a-hydroxy-5a-pregnan-20-one in male and female rats.Alcoholism ClinExp Res22: 2055-2061.
37. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988). Pharmacology of risperidone (R64 766), anew antipsychotic with serotonin-S2 and dopamine-D2-antag-onistic properties.J PharmacolExpTher244: 685-693.
38. Jung-Testas I, Do Thi A, Koenig H, Desarnaud F, Shazand K, Schumacher M (1999). Progesterone as a neurosteroid: synthesisand actions in rat glial cells.J Steroid BiochemMolBiol69:97-107.
39. Jung-Testas I, Renoir M, Bugnard H, Greene GL, Baulieu E-E (1992). Demonstration of steroid hormone receptors and steroidaction in primary cultures of rat glial cells.J Steroid BiochemMolBiol41: 621-631.
40. Kapur K, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2and D2receptor occupancyof clozapine, risperidone, and olanzapine in schizophrenia.Am JPsychiatry156: 286-293.
41. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AAet al(1998). 5-HT2and D2receptor occupancy of olanzapine inschizophrenia: a PET investigation.Am J Psychiatry155: 921-928.
42. Karavolas HJ, Hodges DR, O’Brien DJ, Mackenzie KM (1979).Invivouptake of [3H]progesterone and [3H]-5a-dihydroprogester-one by rat brain and pituitary and effects of estradiol and time:tissue concentration of progesterone itself of specific metabolites?Endocrinology104: 1418-1425.
43. Keck PE, Strakowski SM, McElroy SL (2000). The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.J ClinPsychiatry61(Suppl 3): 4-9.
44. Kelly DL, Conley RR, Tamminga CA (1999).Differential olanza-pine plasma concentrations by sex in a fixed-dose study.Schizophrenia Res40: 101-104.
45. Khisti RT, Deshpande LS, Chopde CT (2002). The neurosteroid 3a-hydroxy-5a-pregnan-20-one affects dopamine mediated behavior in rodents.Psychopharmacology161: 120-128.
46. Khisti RT, Mandhane SN, Chopde CT (1998). The neurosteroid 3a-hydroxy-5a-pregnan-20-one induces catalepsy in mice.NeurosciLett251: 85-88.
47. Kinkead B, Shahid S, Owens MJ, Nemeroff CB (2000). Effects of acute and subchronic administration of typical and atypicalantipsychotic drugs on the neurotensin system of the rat brain.JPharmacolExpTher295: 67-73.
48. Koenig HL, Schumacher M, Ferzaz B, Do Thi AN, Ressouches A, Guennoun Ret al(1995). Progesterone synthesis and myelinformation by Schwann cells.Science268: 1500-1503.
49. Kokate TG, Cohen AL, Karp E, Rogawski MA (1996). Neuroactive steroids protect against pilocarpine- and kainic acid-inducedlimbic seizures and status epilepticus in mice.Neuropharmacol-ogy35: 1049-1056.
50. Kokate TG, Svensson BE, Rogawski MA (1994). Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyricacid-evoked chloride current potentiation.J PharmacolExpTher270: 1223-1229.
51. Lewis DA (2000). GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.Brain Res Rev31:270-276.
52. Lieberman JA, Tohen M, McEvoy J, Sanger T, Keefe R, HGDH Study Group (2000). Olanzapine versushaloperidol in the treatment of first-episode psychosis. Abstractsof the 39th American College of NeuropsychopharmacologyMeeting, December 2000.
53. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A (1998). Proton magnetic resonance spectro-scopic imaging of cortical gray and white matter in schizo-phrenia.Arch Gen Psychiatry55: 346-352.
54. Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pfefferbaum A (1999). Compromised white matter tract integrityin schizophrenia inferred from diffusion tensor imaging.ArchGen Psychiatry56: 367-374.
55. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986). Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.Science232: 1004-1007.
56. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL (2000). Olanzapine increases allopregnanolone in the ratcerebral cortex.Biological Psychiatry47: 1000-1004.
57. Marx CE, Lieberman JA (1998). Psychoneuroendocrinology of schizophrenia. In: Nemeroff C (ed).Psychiatric Clinics of NorthAmerica.WB Saunders, Philadelphia, PA 21: 413-434.
58. McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka Ret al(1998). Olanzapine in treatment-resistant bipolar disorder.JAffect Disord49: 119-122.
59. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJet al(1994). Survey on the pharmacodynamics ofthe new antipsychotic risperidone.Psychopharmacology114:9-23.
60. Meltzer HY (2001). Treatment of suicidality in schizophrenia.Ann NY AcadSci932: 44-58.
61. Meltzer HY, Myung AL, Jayathilake K (2001). The blunted plasma cortisol response to apomorphine and its relationship totreatment response in patients with schizophrenia.Neuropsy-chopharmacology24: 278-290.
62. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.Am J Psychiatry152: 183-190.
63. Moore NA, Rees G, Sanger G, Tye NC (1994).Effects of olanzapine and other antipsychotic agents on responding maintained by aconflict schedule.BehavPharmacol5: 196-202.
64. Moore NA, Tye NC, Axton MS, Risius FC (1992).The behavioral pharmacology of olanzapine, a novel ‘atypical’ antipsychoticagent.J PharmacolExpTher262: 545-551.
65. Morrow AL, Devaud LL, Purdy RH, Paul SM (1995).Neuroactive steroid modulators of the stress response.Ann NY AcadSci771:257-272.
66. Morrow AL, Pace JR, Purdy RH, Paul SM (1990). Characterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroidrecognition sites.MolPharmacol37: 263-270.
67. Morrow AL, Suzdak PD, Paul SM (1987). Steroid hormone metabolites potentiate GABA receptor-mediated chlorideion flux with nanomolar potency.Eur J Pharmacol142:483-485.
68. Motzo C, Porceddu ML, Maira G, Flore G, Concas A, Dazzi Let al(1996). Inhibition of basal and stress-induced dopamine releasein the cerebral cortex and nucleus accumbens of freely movingrats by the neurosteroidallopregnanolone.J Psychopharmacol10: 266-272.
69. Mukherjee J, Christian BT, Narayanan TK, Bingzhi S, Mantil J (2001). Evaluation of dopamine D-2 receptor occupancy byclozapine, risperidone, and haloperidolin vivoin the rodent andnonhuman primate brain using18F-fallypride.Neuropsychophar-macology25: 476-488.
70. Opstad PK (1992). Androgenic hormones during prolonged physical stress, sleep, and energy deficiency.J ClinEndocrinolMetab74: 1176-1183.
71. Patchev VK, Hassan AHS, Holsboer F, Almeida OFX (1996). The neurosteroidtetrahydroprogesterone attenuates the endocrineresponse to stress and exerts glucocorticoid-like effects onvasopressin gene transcription in the rat hypothalamus.Neuropsychopharmacology15: 533-540.
72. Patchev VK, Shoaib M, Holsboer F, Almeida OFX (1994). The neurosteroidtetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release andgene expression of corticotropin-releasing hormone in the rathypothalamus.Neuroscience62: 265-271.
73. Paul SM, Purdy RH (1992). Neuroactive steroids.FASEB J6: 2311-2322.
74. Pepe GJ, Rothchild I (1973). Metabolic clearance rate of progesterone: comparison between ovariectomized, pregnant, pseudopregnant and deciduoma-bearing pseudopregnant rats.Endocrinology93: 1200-1205.
75. Purdy RH, Moore PH, Rao PN, Hagino N, Yamaguchi T, Schmidt Pet al(1990). Radioimmunoassay of 3a-hydroxy-5a-pregnan-20-one in rat and human plasma.Steroids55: 290-296.
76. Purdy RH, Morrow AL, Moore PH, Paul SM (1991). Stress-induced elevations of g-aminobutyric acid type A receptor-active steroidsin the rat brain.ProcNatlAcadSci USA88: 4553-4557.
77. Raisingham KH, Dorfman R, Forchielli E, Gyermak L, Genther G (1968). Uptake of intravenously administered progesterone, pregnanedione and pregnanolone by the rat brain.ActaEndocrinol57: 395-404.
78. Ranjan R, Meltzer HY (1995). Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression.BiolPsychiatry40: 253-258.
79. Romeo E, Str A, Spalletta G, di Michele F, Hermann B, Holsboer Fet al(1998). Effects of antidepressant treatment onneuroactive steroids in major depression.Am J Psychiatry155:910-913.
80. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF (2001). Long-term olanzapine therapy in thetreatment of bipolar I disorder: an open-label continuationphase study.J Clin Psychiatry62: 273-281.
81. Seeman M (1986). Current outcome in schizophrenia: women vs men.ActaPsychiatrScand73: 609-617.
82. Seeman M (1995). Gender differences in treatment response to schizophrenia. In: Seeman MV (ed).Gender and Psychopathol-ogy. Washington, DC: American Psychiatric Press, pp 227-268.
83. Seeman MV (1997). Psychopathology in women and men: focus on female hormones.Am J Psychiatry154: 1641-1647.
84. Serra M, Littera M, Pisu MG, Muggironi M, Purdy RH, Biggio G (2000). Steroidogenesis in rat brain induced by short- and long-term administration of carbamazepine.Neuropharmacology39:2448-2456.
85. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TGet al(2001). A novel augmentation strategy for treatingresistant major depression.Am J Psychiatry158: 131-134.
86. Sigmundsson T, Suckling J, Maier M, Williams SCR, Bullmore ET, Greenwood KEet al(2001). Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white mattertracts in schizophrenic patients with prominent negativesymptoms.Am J Psychiatry158: 234-243.
87. Simpson GM, Yadalam KG, Levinson DF, Stephanos MJ, Lo ES, Cooper TB (1990).Single dose pharmacokinetics of fluphenazineafter fluphenazinedecanoate administration.J ClinPsychopharmacol10: 417-421.
88. Spealman RD, Katz JL (1980). Some effects of clozapine on punished responding by mice and squirrel monkeys.J PharmacolExpTher212: 435-440.
89. Strohle A, Pasini A, Romeo E, Hermann B, Spalletta G, Dimichele Fet al(2000). Fluoxetine decreases concentrations of 3a, 5a-tetrahydrodeoxycorticosterone (THDOC) in major depression.JPsychiatric Res34: 183-186.
90. Strohle A, Romeo E, Hermann B, Pasini A, Spalletta G, Dimichele Fet al(1999). Concentrations of 3a-reduced neuroactive steroidsand their precursors in plasma of patients with major depressionand after clinical recovery.Biol Psychiatry45: 274-277.
91. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999). Clinical outcome in a randomized 1-year trial ofclozapine versus treatment as usual for patients with treat-ment-resistant illness and a history of mania.Am J Psychiatry156: 1164-1169.
92. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler Set al(1995). Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episodeschizophrenic patients.Am J Psychiatry152: 698-703.
93. Szymanski S, Lieberman JA, Pollack S, Kane JM, Safferman A, Munne Ret al(1996). Gender differences in neurolepticnonresponsive clozapine-treated schizophrenics.Biol Psychiatry39: 249-254.
94. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PGet alfor the Olanzapine HGGW Study Group (2000). Efficacyof olanzapine in acute bipolar mania: a double-blind, placebocontrolled study.Arch Gen Psychiatry 57: 841-849.
95. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa RKN, Daniel DGet althe Olanzapine HGEH Study Group (1999).Olanzapine versus placebo in the treatment of acute mania.Am JPsychiatry156: 702-709.
96. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RNet al(1997). Olanzapine versus haloperidol in the treatmentof schizophrenia and schizoaffective and schizophreniformdisorders: results of an international collaborative trial.Am JPsychiatry154: 457-465.
97. Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998). A doubleblind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptomsaccompanying schizophrenia.Biol Psychiatry43: 803-810.
98. Uzunov DP, Cooper TB, Costa E, Guidotti A (1996). Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography.ProcNatlAcadSci USA93:12599-12604.
99. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998). Increase in the cerebrospinal fluid contentof neurosteroids in patients with unipolar major depression whoare receiving fluoxetine or fluvoxamine.ProcNatlAcadSci USA95: 3239-3244.
100. VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL (2000). Neuroactive steroid 3a-hydroxy-5a-pregnan-20-one modulates electrophysiological and behavioral actions ofethanol.J Neurosci20: 1982-1989.
101. Walker DQ, Francis R, Cabassa J, Kuhn CM (2001). Effect of ovarian hormones and estrous cycle on stimulation of thehypothalamo-pituitary-adrenal axis by cocaine.J PharmacolExpTher297: 291-298.
102. Weinberger DR, Berman KF, Illowsky BP (1988). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia:III. A new cohort and evidence for a monoaminergicmechan-ism.Arch Gen Psychiatry45: 609-615.
103. Wieland S, Lan NC, Mirasedeghi S, Gee KW (1991). Anxiolytic activity of the progesterone metabolite 5a-pregnan-3a-ol-20-one.Brain Res565: 263-268.
104. Wiley JL, Compton AD, Porter JH (1993). Effects of four antipsychotics on punished responding in rats.PharmacolBiochemBehav45: 263-267.
105. Zarate CA, Tohen M, Baldessarini RJ (1995). Clozapine in severe mood disorders.J Clin Psychiatry56: 411-417.
106. Zhang W, Bymaster FP (1999). Thein vivoeffects of olanzapine and other antipsychotic agents on receptor occupancy andantagonism of dopamine Dj, D2, D3, 5HT2Aand muscarinicreceptors.Psychopharmacology141: 267-278.
107. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GDet al(2000). Synergistic effects of olanzapine and other antipsychoticagents in combination with fluoxetine on norepinephrine anddopamine release in rat prefrontal cortex.Neuropsychopharma-cology23: 250-262.